[go: up one dir, main page]

BR9912275A - Formulação de bioimplante - Google Patents

Formulação de bioimplante

Info

Publication number
BR9912275A
BR9912275A BR9912275-8A BR9912275A BR9912275A BR 9912275 A BR9912275 A BR 9912275A BR 9912275 A BR9912275 A BR 9912275A BR 9912275 A BR9912275 A BR 9912275A
Authority
BR
Brazil
Prior art keywords
weight
formulation
bioimplant
approximately
active agent
Prior art date
Application number
BR9912275-8A
Other languages
English (en)
Inventor
Timothy Elliot Trigg
John Desmond Walsh
Deborah Ann Rathjen
Original Assignee
Peptech Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AUPP4731A external-priority patent/AUPP473198A0/en
Priority claimed from AUPP4730A external-priority patent/AUPP473098A0/en
Priority claimed from AUPQ0324A external-priority patent/AUPQ032499A0/en
Application filed by Peptech Ltd filed Critical Peptech Ltd
Publication of BR9912275A publication Critical patent/BR9912275A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

<B>FORMULAçãO DE BIOIMPLANTE<D> Uma formulação farmacêutica e/ou veterinária compreendendo aproximadamente 2-30% (peso/peso) (em uma base ativa) de pelo menos um agente ativo, aproximadamente 0,5-20,0% (peso/peso) de um agente formador de poros e o restante estearina. Tais formulações fornecem liberação contínua de pelo menos um agente ativo em seres humanos e outros animais por períodos de 7 dias até aproximadamente 2 anos.
BR9912275-8A 1998-07-20 1999-07-20 Formulação de bioimplante BR9912275A (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
AUPP4731A AUPP473198A0 (en) 1998-07-20 1998-07-20 Bioimplant formulation II
AUPP4730A AUPP473098A0 (en) 1998-07-20 1998-07-20 Bioimplant formulation I
AUPQ0324A AUPQ032499A0 (en) 1999-05-13 1999-05-13 Bioimplant formulation iii
PCT/AU1999/000585 WO2000004897A1 (en) 1998-07-20 1999-07-20 Bioimplant formulation

Publications (1)

Publication Number Publication Date
BR9912275A true BR9912275A (pt) 2001-04-17

Family

ID=27158088

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9912275-8A BR9912275A (pt) 1998-07-20 1999-07-20 Formulação de bioimplante

Country Status (9)

Country Link
US (2) US6913761B1 (pt)
EP (1) EP1104296B1 (pt)
JP (1) JP2002521331A (pt)
CN (1) CN1243543C (pt)
BR (1) BR9912275A (pt)
CA (1) CA2336879C (pt)
ES (1) ES2389627T3 (pt)
MX (1) MXPA01000674A (pt)
WO (1) WO2000004897A1 (pt)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR9912275A (pt) * 1998-07-20 2001-04-17 Peptech Ltd Formulação de bioimplante
US8052982B2 (en) * 1998-07-20 2011-11-08 Peptech Animal Health Pty Limited Bioimplant formulation comprising lecithin and stearin
EP1267914B2 (en) * 2000-02-04 2013-11-06 Children's Hospital Research Foundation Use of lysosomal acid lipase for treating atherosclerosis and related diseases
US7109171B2 (en) * 2000-02-28 2006-09-19 Praecis Pharmaceuticals Inc. Methods for treating FSH related conditions with GnRH antagonists
EP1335704A2 (en) * 2000-11-16 2003-08-20 Durect Corporation Implant dosage form and use thereof for the delivery of a cholesterol lowering agent
NZ538928A (en) * 2002-09-27 2006-10-27 Zentaris Gmbh Administration form for pharmaceutically active peptides with sustained release of active ingredient, and method for the production thereof
AU2004313245B2 (en) 2003-12-30 2011-04-14 Durect Corporation Polymeric implants, preferably containing a mixture of PEG and PLG, for controlled release of active agents, preferably a GNRH
WO2005117934A1 (en) * 2004-05-31 2005-12-15 Smart Drug Systems Inc Sustained release composition
US20080254086A1 (en) * 2004-12-23 2008-10-16 Brown James E Controlled Release Compositions
US20090297496A1 (en) * 2005-09-08 2009-12-03 Childrens Hospital Medical Center Lysosomal Acid Lipase Therapy for NAFLD and Related Diseases
CA2683517A1 (en) * 2007-04-23 2008-10-30 Bayer Schering Pharma Aktiengesellschaft Combination of progesterone-receptor antagonist together with a lutein-hormone-releasing hormone agonist and antagonist for use in brca mediated diseases
JOP20090061B1 (ar) 2008-02-11 2021-08-17 Ferring Int Center Sa طريقة معالجة سرطان البروستاتا بمضادات الهرمونات التناسلية GnRH
US20110092493A1 (en) * 2008-09-24 2011-04-21 Clark Levi Dose-controlled transdermal promethazine compositions and methods of use
CA3228586A1 (en) * 2012-06-01 2013-12-05 Ferring B.V. Manufacture of degarelix
EP2832361A1 (en) * 2013-07-29 2015-02-04 Ipsen Pharma S.A.S. Aqueous sustained release compositions of LHRH analogs
WO2015026423A1 (en) 2013-08-20 2015-02-26 Infusion Medical, Inc. Syringe fill system and method
USD750768S1 (en) 2014-06-06 2016-03-01 Anutra Medical, Inc. Fluid administration syringe
USD763433S1 (en) 2014-06-06 2016-08-09 Anutra Medical, Inc. Delivery system cassette
USD774182S1 (en) 2014-06-06 2016-12-13 Anutra Medical, Inc. Anesthetic delivery device
US20180177777A1 (en) * 2016-12-28 2018-06-28 Michael Ballek Formulations for mitigating opioid overdose and methods of making and using the same

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4578391A (en) * 1982-01-20 1986-03-25 Yamanouchi Pharmaceutical Co., Ltd. Oily compositions of antitumor drugs
FR2573307B1 (fr) * 1984-11-22 1988-06-10 Virbac Ctre Rech Biolog Implants anabolisants a liberation prolongee
US5179079A (en) * 1986-12-16 1993-01-12 Novo Nordisk A/S Nasal formulation and intranasal administration therewith
EP0353045B1 (en) * 1988-07-26 1995-11-15 Rutgers, The State University of New Jersey Devices and methods for growth promotion in poultry roasters
US4981681A (en) * 1988-08-26 1991-01-01 Vittorio Tosti Lotion mixture and method of treating psoriasis
AU6430190A (en) * 1989-10-10 1991-05-16 Pitman-Moore, Inc. Sustained release composition for macromolecular proteins
CA2068216C (en) * 1989-11-13 1999-04-13 Abraham J. Domb Lipospheres for controlled delivery of substances
SG47955A1 (en) 1991-06-24 1998-04-17 American Cyanamid Co Implant compositions containing a biologically active protein peptide or polypeptide
SI9300468A (en) * 1992-10-14 1994-06-30 Hoffmann La Roche Injectable composition for the sustained release of biologically active compounds
AUPN366795A0 (en) * 1995-06-20 1995-07-13 Peptide Technology Limited Formulation for preventing reproductive function
US5736152A (en) * 1995-10-27 1998-04-07 Atrix Laboratories, Inc. Non-polymeric sustained release delivery system
NZ334236A (en) * 1996-08-30 2000-06-23 Peptech Ltd Composition comprising GnRH, lecithin and stearin
EP0945133A1 (en) * 1998-03-26 1999-09-29 Lipha Combination for the treatment of alcohol and drug dependence containing an opioid antagonist and a NMDA receptor complex modulator
BR9912275A (pt) * 1998-07-20 2001-04-17 Peptech Ltd Formulação de bioimplante

Also Published As

Publication number Publication date
CA2336879A1 (en) 2000-02-03
JP2002521331A (ja) 2002-07-16
US20050276854A1 (en) 2005-12-15
ES2389627T3 (es) 2012-10-29
US6913761B1 (en) 2005-07-05
EP1104296A4 (en) 2004-11-10
CA2336879C (en) 2010-06-01
EP1104296A1 (en) 2001-06-06
CN1243543C (zh) 2006-03-01
MXPA01000674A (es) 2002-04-08
EP1104296B1 (en) 2012-06-13
WO2000004897A1 (en) 2000-02-03
CN1310623A (zh) 2001-08-29

Similar Documents

Publication Publication Date Title
BR9912275A (pt) Formulação de bioimplante
NO962040D0 (no) Mikroinnkapslede 3-piperidinyl-substituerte 1,2-benzisoksazoler og 1,2-benzisotiazoler
BR9200252A (pt) Agente para aplicacao oral,peca moldada para aplicacao oral,produto,processo para a preparacao de um agente,processo para preparacao de pecas moldadas e aplicacao de uma peca moldada
ES2139021T3 (es) Composiciones germicidas de detergente-yodo que tienen un contenido reducido de detergente.
BRPI0408655A (pt) formulações compreendendo um agente ativo e cacau em pó e a sua utilização
ES2133412T3 (es) 2&#39;,5&#39;-oligoadenilato-2&#39;,3&#39;-ciclofosfatos y 2&#39;,5&#39;-oligoadenilatos con actividad sobre el virus papiloma.
MX9205384A (es) Dispositivo de administracion transdermica de un agente activo para uso veterinario.
ATE220547T1 (de) Arzneimittelformulierung mit kontrollierter wirkstofffreisetzung
CO5221025A1 (es) 4-trifluorometil-3-oxazolilpiridinas, procedimiento para su preparacion, agentes que las contienen y su uso como agente para la lucha contra organismos daninos
PT1150686E (pt) Matriz directamente compressivel para libertacao controlada de doses diarias unitarias de claritromicina
DK1330258T3 (da) Kahalalid F-formulering
BR9916620A (pt) Derivados de fenetil-5-bromopiridiltiouréia (pbt) e diidroalcoxibenziloxopirimidina (dabo) exibindo atividade espermicida
NZ219300A (en) Veterinary composition for release of actives into the rumen
ES2182983T3 (es) Formulaciones para la liberacion de peptidos.
DE69002533D1 (de) Indan-1,3-dionderivate und herbizide zusammensetzungen, die diese als aktiven bestandteil enthalten.
NO20031650D0 (no) Nye legemidler for leversykdommer
ITRM990339A0 (it) Derivati di principi attivi ad attivita&#39; terapeutica e/o nutrizionalee composizioni atte alla somministrazione orale contenenti tali deriva
HRP20020071B1 (en) Pharmaceutical composition and preparation thereof
BR0014058A (pt) Produto sólido, composição, solução aquosa de 4,4-dimetil-5a-colesta-8,14,24-triene-3(beta) -ol, e, dispositivo tendo uma concavidade
TR200001075T2 (tr) Tiamfenikol ve diklofenak içeren bileşimler.
BR0112369A (pt) Anti-helmìnticos para evitar infecções parasitárias no homem e animal ii
BR0202759A (pt) Composição farmacêutica de liberação modificada contendo bupropiona como substância ativa
BR9915897A (pt) Agentes de transferência de ácidos nucleicos, composição, utilização de um agente de transferência e processos de tratamento de corpo humano ou animal e de transferência de ácidos nucleicos.
ES2181253T3 (es) Solucion acuosa de enteroclisis para el tratamiento de la encefalopatia hepatica.
BR0112230A (pt) Anti-helmìnticos para prevenção de infecções parasitárias em seres humanos e animais

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: ALTERADA DA INT.CL: A61K 9/00, A61K 9/70, A61K 31/485, A61K 38/00, A61K 45/00

Ipc: A61K 9/00 (2009.01), A61K 9/70 (2009.01), A61K 31/

B25D Requested change of name of applicant approved

Owner name: ARANA THERAPEUTICS LIMITED (AU)

Free format text: ALTERADO DE: PEPTECH LIMITED

B25G Requested change of headquarter approved

Owner name: ARANA THERAPEUTICS LIMITED (AU)

Free format text: SEDE ALTERADA CONFORME SOLICITADO NA PETICAO NO 020090014718/RJ DE 12/02/2009.

B25A Requested transfer of rights approved

Owner name: PEPTECH ANIMAL HEALTH PTY LIMITED (AU)

Free format text: TRANSFERIDO DE: ARANA THERAPEUTICS LIMITED

B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFERIDO O PEDIDO COM BASE NOS ARTIGOS 8O, 13, 24 E 25 DA LPI.

B12B Appeal against refusal [chapter 12.2 patent gazette]